Study Sponsor
The reLiver-1 trial is sponsored by Unicyte AG
Unicyte AG is a regenerative medicine company with a focus on kidney and liver disorders, diabetes and oncology, headquartered in Oberdorf NW, Switzerland.
Evolution of 15 years of research
Unicyte is the evolution of a fifteen-year research collaboration between Prof. Camussi’s research group at the University of Turin and Fresenius Medical Care.
This research focuses on adult human liver stem cells (HLSC), that have multiple differentiating and self-renewing capabilities. HLSC are generated in a master cell bank and prepared for use as an investigational medical product in Unicyte’s clinical trials.
Unicyte AG is a regenerative medicine company with a focus on kidney and liver disorders, diabetes and oncology, headquartered in Oberdorf NW, Switzerland.
